Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29386458 | 1.00 | HDAC8 (0.55) | HDAC8HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29990582 | 1.00 | HDAC8 (0.55) | HDAC8HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29991896 | 1.00 | HDAC8 (0.55) | HDAC8HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL18374697 | 1.00 | HDAC8 (0.55) | HDAC8HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL25123876 | 1.00 | HDAC8 (0.55) | HDAC8HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL25123844 | 1.00 | HDAC8 (0.55) | HDAC8HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL30601912 | 1.00 | HDAC8 (0.55) | HDAC8HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29387341 | 0.98 | CYP1A2 (0.53) | HDAC8HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL18374069 | 0.98 | CYP1A2 (0.53) | HDAC8HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL9970727 | 0.94 | CYP1A2 (0.58) | KMT2ACYP1A2CYP2C19CYP2D6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188039-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2025-06-12 | — | — | US | disclosed |
| EP-3319939-B1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS NI LTD (GB) | 2024-11-27 | — | — | EP | disclosed |
| US-12098133-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2024-09-24 | — | — | US | disclosed |
| US-20230126280-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-04-27 | — | — | US | disclosed |
| US-20230126280-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-04-27 | — | — | US | disclosed |
| US-20230126280-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-04-27 | — | — | US | disclosed |
| US-11584723-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-20220402879-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-12-22 | — | — | US | disclosed |
| US-20220402879-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-12-22 | — | — | US | disclosed |
| US-11518746-B2 | Nitrogen ring linked deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-12-06 | — | — | US | disclosed |
| US-20150004181-A1 | Benzazole Derivatives as Histamine H4 Receptor Ligands | BIOPROJET SOC CIV (FR) | 2015-01-01 | — | — | US | disclosed |
| US-8802664-B2 | Benzazole derivatives as histamine H4 receptor ligands | BIOPROJECT (FR) | 2014-08-12 | — | — | US | disclosed |
| US-20130231329-A1 | Benzazole Derivatives as Histamine H4 Receptor Ligands | BIOPROJET (FR) | 2013-09-05 | — | — | US | disclosed |
| EP-2621916-A1 | BENZAZOLE DERIVATIVES AS HISTAMINE H4 RECEPTOR LIGANDS | BIOPROJET (FR) | 2013-08-07 | — | — | EP | disclosed |
| EP-2447263-A1 | Benzazole derivatives as histamine H4 receptor ligands | BIOPROJET (FR) | 2012-05-02 | — | — | EP | disclosed |
| WO-2012041860-A1 | BENZAZOLE DERIVATIVES AS HISTAMINE H4 RECEPTOR LIGANDS | BIOPROJET (FR) | 2012-04-05 | — | — | WO | disclosed |
| EP-1242076-A4 | 2-BENZYL AND 2-HETEROARYL BENZIMIDAZOLE NMDA/NR2B ANTAGONISTS | MERCK & CO INC (US) | 2002-11-27 | — | — | EP | disclosed |
| EP-1242076-A1 | 2-BENZYL AND 2-HETEROARYL BENZIMIDAZOLE NMDA/NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6316474-B1 | TREATMENT OF PAIN, SCHIZOPHRENIA, PARKINSON'S DISEASE, STROKE AND DEPRESSION | MERCK & CO., INC. | 2001-11-13 | — | — | US | disclosed |
| WO-2001032174-A1 | 2-BENZYL AND 2-HETEROARYL BENZIMIDAZOLE NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150004181-A1 | Benzazole Derivatives as Histamine H4 Receptor Ligands | HRH4, HRH3, HRH2 | HDAC8 440/4885HDAC3 235/4885HDAC4 102/4885 |
| US-11584723-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | HDAC8 608/4885HDAC3 899/4885HDAC4 1236/4885 |
| US-20220402879-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | HDAC8 608/4885HDAC3 899/4885HDAC4 1236/4885 |
| US-20250188039-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | HDAC8 608/4885HDAC3 899/4885HDAC4 1236/4885 |
| US-11518746-B2 | Nitrogen ring linked deoxyuridine triphosphatase inhibitors | DUT, DPYD, TYMP | HDAC8 1546/4885HDAC3 2006/4885HDAC4 2427/4885 |
| US-12098133-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | HDAC8 608/4885HDAC3 899/4885HDAC4 1236/4885 |
| US-20130231329-A1 | Benzazole Derivatives as Histamine H4 Receptor Ligands | HRH4, HRH3, HRH2 | HDAC8 653/4885HDAC3 311/4885HDAC4 195/4885 |
| US-20230126280-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | HDAC8 608/4885HDAC3 899/4885HDAC4 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.